COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,761 Articles (22,502 medRxiv, 8,259 bioRxiv)

Most recent first Previous |  Page 1004: Articles 10031-10040  | Next

Context-specific emergence and growth of the SARS-CoV-2 Delta variant
McCrone, J. T., Hill, V., Bajaj, S., Evans Pena, R., Lambert, B. C., Inward, R., Bhatt, S., Volz, E., Ruis, C., Dellicour, S., Baele, G., Zarebski, A. E., Sadilek, A., Wu, N., Schneider, A., Ji, X., Raghwani, J., Jackson, B., Colquhoun, R., O'Toole, A., Peacock, T. P., Twohig, K., Thelwall, S., Dabrera, G., Myers, R., The COVID-19 genomics UK (COG-UK) consortium, , Faria, N. R., Huber, C., Bogoch, I. I., Khan, K., Plessis, L. d., Barrett, J. C., Aanensen, D. M., Barclay, W. S., Chand, M., Connor, T., Loman, N. J., Suchard, M. A., Pybus, O. G., Rambaut, A., Kraemer, M. U. G.
10.1101/2021.12.14.21267606 — Posted: 2021-12-21
Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma
Sullivan, D. J., Gebo, K. A., Shoham, S., Bloch, E. M., Lau, B., Shenoy, A. G., Mosnaim, G. S., Gniadek, T. J., Fukuta, Y., Patel, B., Heath, S. L., Levine, A. C., Meisenberg, B. R., Spivak, E. S., Anjan, S., Huaman, M. A., Blair, J. E., Currier, J. S., Paxton, J. H., Gerber, J. M., Petrini, J. R., Broderick, P. B., Rausch, W., Cordisco, M. E., Hammel, J., Greenblatt, B., Cluzet, V. C., Cruser, D., Oei, K., Abinante, M., Hammit, L. L., Suttcliffe, C. G., Forthal, D. N., Zand, M. S., Cachay, E. R., Raval, J. S., Kassaye, S. G., Foster, C., Roth, M., Marshall, C. E., Yarava, A., Lane, K., McBee, N. A., Gawad, A. L., Karlen, N., Singh, A., Ford, D. E., Jabs, D. A., Appel, L. J., Shade, D. M., Ehrhardt, S., Baksh, S. N., Laeyendecker, O., Pekosz, A., Klein, S., Casadevall, A., Tobian, A. A., Hanley, D. F.
10.1101/2021.12.10.21267485 — Posted: 2021-12-21
Binding and Neutralizing Antibody Responses to SARS-CoV-2 in Infants and Young Children Exceed Those in Adults
Karron, R. A., Quesada, M. G., Schappell, E. A., Schmidt, S. D., Knoll, M. D., Hetrich, M. K., Veguilla, V., Doria-Rose, N., Dawood, F. S., SEARCh Study Team
10.1101/2021.12.20.21268034 — Posted: 2021-12-21
SARS-CoV-2 spike conformation determines plasma neutralizing activity
Bowen, J. E., Walls, A. C., Joshi, A., Sprouse, K. R., Stewart, C., Tortorici, M. A., Franko, N. M., Logue, J. K., Mazzitelli, I. G., Tiles, S. W., Ahmed, K., Shariq, A., Snell, G., Iqbal, N. T., Geffner, J., Bandera, A., Gori, A., Grifantini, R., Chu, H. Y., Van Voorhis, W. C., Corti, D., Veesler, D.
10.1101/2021.12.19.473391 — Posted: 2021-12-21
Arsenal of Nanobodies for Broad-Spectrum Countermeasures against Current and Future SARS-CoV-2 Variants of Concerns
Rossotti, M. A., van Faassen, H., Tran, A., Sheff, J., Sandhu, J. A., Duque, D., Hewitt, M., Wen, S., Bavananthasivam, R., Beitari, S., Matte, K., Laroche, G., Giguere, P. M., Gervais, C., Stuible, M., Guimond, J., Perret, S., Hussack, G., Langlois, M.-A., Durocher, Y., Tanha, J.
10.1101/2021.12.20.473401 — Posted: 2021-12-21
The P3 O-Tert-Butyl-Threonine is Key to High Cellular and Antiviral Potency for Aldehyde-Based SARS-CoV-2 Main Protease Inhibitors
Ma, Y., Yang, K., Geng, Z. Z., Alugubellia, Y. R., Shaabani, N., Vatansever, E. C., Ma, X. R., Cho, C.-C., Khatua, K., Blankenship, L., Yu, G., Sankaran, B., Li, P., Allen, R., Ji, H., Xu, S., Liu, W. R.
10.1101/2021.12.18.473326 — Posted: 2021-12-21
SARS-CoV-2 Omicron Variant: ACE2 Binding, Cryo-EM Structure of Spike Protein-ACE2 Complex and Antibody Evasion
Mannar, D., Saville, J. W., Zhu, X., Srivastava, S. S., Berezuk, A. M., Tuttle, K., Marquez, C., Sekirov, I., Subramaniam, S.
10.1101/2021.12.19.473380 — Posted: 2021-12-21
Human genetic variants associated with COVID-19 severity are enriched in immune and epithelium regulatory networks
Feng, Z., Ren, X., Duren, Z., Wang, Y.
10.1101/2021.12.17.473140 — Posted: 2021-12-21
SARS-CoV-2 Omicron spike mediated immune escape, infectivity and cell-cell fusion
Meng, B., Ferreira, I., Abdullahi, A., Kemp, S. A., Goonawardane, N., Papa, G., Fatihi, S., Charles, O., Collier, D., CITIID-NIHR BioResource COVID-19 Collaboration, , The Genotype to Phenotype Japan (G2P-Japan) Consortium, , Choi, J., Hyeon Lee, J., Mlcochova, P., James, L., Doffinger, R., Thukral, L., Sato, K., Gupta, R. K.
10.1101/2021.12.17.473248 — Posted: 2021-12-21
A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors
Chen, K.-Y., Krischuns, T., Ortega Varga, L., Harigua-Souiai, E., Paisant, S., Zettor, A., Chiaravalli, J., Courtney, D., O'Brien, A., Baker, S., Isel, C., Agou, F., Jacob, Y., Blondel, A., Naffakh, N.
10.1101/2021.12.18.473303 — Posted: 2021-12-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).